We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Acuitas Therapeutics

Founded by Drs. Thomas Madden, Michael Hope and Pieter Cullis in 2009, Acuitas Therapeutics is a Vancouver-based biotechnology company with a global reputation for innovation and excellence. They are strategically focused on working with their partners to advance nucleic acid therapeutics enabled by their best-in-class lipid nanoparticle (LNP) delivery platform.

Latest Content

A newborn baby in hospital with a nurse leaning over administering treatment in preparation for LNP-mediated gene therapy.

Industry Insight

Building the Next Generation of Genetic Medicines With LNPs

A recent milestone study used the LNP delivery system developed by Acuitas Therapeutics to treat a newborn with urea cycle disorder (UCD) successfully with a personalized CRISPR therapy. We spoke to Dr. Ying Tam, their CSO, to find out more.

Never miss a story

with the Breaking Science News daily newsletter